Aktis Oncology, Inc. reported financial results and business highlights for the quarter ended June 30, 2026. The company held $517.3 million in cash, cash equivalents, and marketable securities as of June 30, 2026, compared to $226.8 million at year-end 2025. Collaboration revenue reached $3.4 million, up from $1.6 million in the prior-year period, driven by advancement with Eli Lilly and Company. Research and development expenses increased to $25.3 million from $18.6 million, while general and administrative expenses rose to $7.0 million from $3.9 million. The company reported a net loss of $24.1 million for the quarter. Clinically, Aktis presented first-in-human imaging data for AKY-2519 at ASCO, continued enrollment in the Phase 1b NECTINIUM-2 trial for AKY-1189, and initiated the Phase 1b BActinium-1 trial for AKY-2519 in metastatic castration-resistant prostate cancer. The company operates as a clinical-stage oncology firm focused on developing targeted radiopharmaceuticals using its proprietary miniprotein platform.